Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 11durvalumab 7Oxaliplatin 5Capecitabine 5Fluorouracil 4S 1 (combination) 3Leucovorin 3Irinotecan 3zanidatamab 2gemcitabine-oxaliplatin regimen 2Trastuzumab 2trastuzumab deruxtecan 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1envafolimab 1encorafenib 1binimetinib 1becatecarin 1Tegafur 1Pancreaticojejunostomy 1NUC-1031 1Folfox protocol 1Drug Therapy 1Chemotherapy, Adjuvant 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Biliary Tract Neoplasms × becatecarin × Clear all
NCT00090025 2009-01-14

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Helsinn Healthcare SA

Phase 3 Terminated
248 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡